ArticleJCO oncology advances2026
Reach, Acceptability, and Effectiveness of Proactive Outreach and Varenicline with Cancer-Focused Counseling for Patients with Cancer: A Pilot Randomized Comparative Effectiveness Trial.
Article in JCO oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeMore research is needed on the acceptability and effectiveness of cigarette smoking cessation treatments for patients with cancer. This pilot comparative effectiveness trial contrasted varenicline therapy combined with cancer-focused counseling versus standard smoking cessation treatment to assess the reach, acceptability, and preliminary effectiveness of targeted treatment offered proactively to adult patients with cancer. PATIENTS AND
methodsElectronic health records identified adult patients via quarterly reports (January-September, 2024) with cancer diagnoses who smoked tobacco in the past year (N=574) for tobacco use treatment outreach. Eligible patients were enrolled from March-November, 2024, in an effectiveness trial comparing standard smoking cessation treatment (2w nicotine patch + 3 counseling calls) with enhanced treatment (12w varenicline + 7 cancer-targeted counseling calls). Follow-up outcome calls were conducted 12- and 26-weeks after a target quit date. Participants reporting no smoking at 26 weeks post-quit were asked to provide a saliva or breath sample to confirm abstinence.
resultsAmong patients eligible at the time of phone outreach (n=406), 52 (12.8%) enrolled in the trial. In both Standard Care (n=26) and Enhanced Care (n=26), at least 23 (88.5%) participants completed some counseling and received study medications. Satisfaction ratings were higher in Enhanced than Standard Care. At 12 weeks post-quit, self-reported 7-day point prevalence abstinence was reported by 6 (23.1%) Standard Care and 9 (34.6%) Enhanced Care participants (OR 1.76, 95%CI 0.52, 5.97). At 26-weeks post-quit, 2 (7.7%) Standard Care and 7 (26.9%) Enhanced Care participants had biochemically confirmed abstinence (OR: 4.4, 95%CI, 0.82-23.8).
conclusionThis pilot study produced evidence supporting the reach, acceptability, and potential effect sizes of enhanced and cancer-focused smoking cessation counseling and medication treatment for adult patients with cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.